Subtype
Biliary Tract Carcinoma
CI-CAN-00001970Explore in graph →
238 active trials3 approved drugs29 evidence items
- NCIt
- C156781
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001970Explore in graph →
Clinical trials
823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (111)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03042182 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma(cholangio) | unknown | Phase 1 / Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 |
| clinicaltrials |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02108145 | Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 70 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma | terminated | Phase 2 | 7 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2019 | clinicaltrials |
| NCT01766219 | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 17 | Wake Forest University Health SciencesOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02053376 | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | completed | Phase 2 | 43 | Nathan Bahary, MDOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | suspended | Phase 2 | 25 | Shi MingOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | terminated | Phase 2 | 29 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03702491 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | unknown | Phase 2 | 138 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | terminated | Phase 2 | 6 | Allina Health SystemOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01007552 | A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts | completed | Phase 2 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01206049 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations(GOC-B-P) | completed | Phase 2 | 88 | Vejle HospitalOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01755013 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01954745 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01718327 | A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma(SUN-CK) | completed | Phase 2 | 53 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02468076 | Radiofrequency Ablation for Biliopancreatic Malignancy(IGNITE-1) | completed | Phase 2 | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01267344 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC(BTC) | completed | Phase 2 | 122 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00975039 | Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | terminated | Phase 2 | 8 | Steba Biotech S.A.OTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT02683538 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | completed | Phase 2 | 196 | Seoul National University HospitalOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT01692704 | Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | completed | Phase 1 / Phase 2 | 12 | University of ZurichOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01073839 | Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. | completed | Phase 1 / Phase 2 | 33 | University of ZurichOTHER | 1 | Sep 18, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01389414 | Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma(Vecti-BIL) | completed | Phase 2 | 89 | Prof. Massimo AgliettaOTHER | 1 | May 28, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 30, 2019source: clinicaltrials